BAVA:CPH
Bavarian Nordic A/S
236,80 DKK
arrow_downward
-1,82%(-4,40) 1D
13 ოქტ, 17:00:00 GMT+2 · DKK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Open
240,00 DKK
High
242,20 DKK
Low
236,80 DKK
Mkt. cap
19,12 მლრდ.
Avg. vol.
179,17 ათ.
Volume
198,62 ათ.
52-wk high
243,70 DKK
52-wk low
171,30 DKK
Shares outstanding
79,27 მლნ.
No. of employees
2 ათ.
Open
240,00 DKK
High
242,20 DKK
Low
236,80 DKK
Mkt. cap
19,12 მლრდ.
Avg. vol.
179,17 ათ.
Volume
198,62 ათ.
52-wk high
243,70 DKK
52-wk low
171,30 DKK
Shares outstanding
79,27 მლნ.
No. of employees
2 ათ.
News stories
From web sources and news partners
GlobeNewswire
·
1 დღის წინ
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S